Trastuzumab Deruxtecan | Enhertu (Trastuzumab Deruxtecan) | Buy Enhertu | Enhertu 100 mg injection price

Trastuzumab Deruxtecan

  • Brand Name: Enhertu
  • API: Trastuzumab Deruxtecan
  • Packaging: 1 Vial/Per Box
  • Strength: 100 mg lyophilized powder for injection
  • Manufacturer Name: Daiichi Sankyo Inc.
Get Price
Categories: , Tags: , , ,

Description

Uses of Enhertu (Trastuzumab Deruxtecan)

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate used in the treatment of:

  • Adult patients with unresectable or metastatic HER2-positive breast cancer who have previously been treated with an anti-HER2-based agents/regimen either in the metastatic setting or in the neoadjuvant setting or adjuvant setting and have established disease recurrence during or within 6 months of completing therapy.
  • Adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have previously been treated with chemotherapy in the metastatic setting or established disease recurrence during or within 6 months of completing adjuvant chemotherapy.
  • Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously been treated with the trastuzumab-based regimen.
  • Adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have previously been treated with systemic therapy.

Dosage & Side Effects

It is not advisable to substitute medicine Enhertu 100 mg injection for or with trastuzumab or ado-trastuzumab emtansine. Slow/interrupt the infusion rate in case of infusion-related symptoms. Permanently discontinue this medicine in case severe infusion reactions occur.

Recommended Dosage for Metastatic Breast Cancer:

The recommended dosage is 5.4 mg per kg given as an intravenous (IV) infusion once every three weeks (21-day cycle) until disease progression or in case of unacceptable toxicity.

Recommended Dosage for Unresectable or Metastatic HER2-Mutant NSCLC:  The recommended dosage is 5.4 mg per kg given as an intravenous (IV) infusion once every three weeks (21-day cycle) until disease progression or in case of unacceptable toxicity.

Recommended Dosage for Locally Advanced or Metastatic Gastric Cancer:  The recommended dosage is 6.4 mg per kg given as an intravenous (IV) infusion once every three weeks (21-day cycle) until disease progression or in case of unacceptable toxicity.

If a scheduled dose is missed or delayed, administer it as promptly as possible; do not wait until the very next scheduled cycle. The schedule of administration needs to be adjusted to maintain a 3-week interval between doses. Administer the Enhertu 100 mg infusion at the dose and rate the patient tolerated in the most recent infusion.

The most commonly reported side effects of Enhertu 100 mg in patients with:

  • Metastatic breast cancer and HER2-mutant NSCLC are nausea, low white blood cell counts, low red blood cell counts, feeling tired, low platelet counts, increased liver function tests, vomiting, hair loss, muscle or bone pain, constipation, decreased appetite, low levels of blood potassium, diarrhea, and cough.
  • HER2-positive gastric or GEJ adenocarcinoma are diarrhea, low red blood cell counts, low levels of blood potassium, low white blood cell counts, low platelet counts, nausea, fever, decreased appetite, increased liver function tests, feeling tired, vomiting, constipation, and hair loss.

Warnings and Precautions

  • The medicine Enhertu 100 mg is moderately emetogenic, which includes delayed nausea and/or vomiting. Prophylactic antiemetic medicines need to be administered as per local institutional guidelines in order to prevent chemotherapy-induced nausea as well as vomiting.
  • Severe, deadly, or critical ILD or interstitial lung disease, including pneumonitis, may establish in those treated with Trastuzumab Deruxtecan. Patients should promptly report fever, dyspnea, cough, or any potential or worsening respiratory symptoms. Monitor patients for ILD signs and symptoms. Promptly inquire for ILD evidence. Evaluate for suspected ILD with the help of radiographic imaging.
  • Critical neutropenia, including febrile neutropenia, may establish in those treated with Enhertu 100 mg injection. Monitor complete blood counts before treatment and before each dose, and as clinically needed. On behalf of the severity of neutropenia, this treatment may require dose reduction or interruption.
  • In those treated with Trastuzumab Deruxtecan left ventricular dysfunction may occur. Reduction in left ventricular ejection fraction (LVEF) has been observed with anti-HER2 therapies, including Trastuzumab Deruxtecan. Evaluate LVEF before treatment and at regular intervals during therapy as clinically needed. Manage LVEF reduction through therapy interruption.
  • As per the mechanism of action, the medication Enhertu can cause fetal harm if used by a pregnant woman. Pregnancy status must be verified in females of reproductive age. Females of reproductive age should use effective contraception while on treatment and for 7 months after the final dose.

FAQ

What does Enhertu contain as an active substance? 

Enhertu specifically contains the active substance Trastuzumab Deruxtecan.

How is Enhertu supplied?

Enhertu is supplied for injection: 100 mg lyophilized powder in a single-dose vial for intravenous use. It is commercially available by prescription only.

How much does Enhertu cost in India?

Get the best Enhertu cost in India. If you want to buy it online, then THE INDIAN PHARMA (TIP) can help you to access this medicinal product at the most competitive price in India through legal channels.

Is the Enhertu Injection Available In India? 

Enhertu is an imported pharmaceutical prescription medicinal product that is not readily available in India. It can be imported against a valid prescription and import permit. THE INDIAN PHARMA (TIP) can help facilitate the supply of Enhertu after fulfilling the legal requirement (if applicable). Please contact us via +919310090915 or dial TOLL-FREE: 1800-889-1064 or write to us at info@theindianpharma.com to buy Enhertu online in India.

Can I get Enhertu even if I am not based in India? 

THE INDIAN PHARMA (TIP) helps patients in accessing Enhertu (Trastuzumab Deruxtecan), not approved in their home country against the valid prescription and in conformity with the local laws and regulations of their respective country.

Where can I get Enhertu at the best price?

In order to get the best price of Enhertu in India and other countries, always buy this medication from a Pharmaceutical Wholesaler Company which is GDP certified. Noida-based THE INDIAN PHARMA (TIP) can offer the best price for Enhertu (Trastuzumab Deruxtecan).

What is the buying procedure of Enhertu?

In order to buy Enhertu injection online, you can contact us at our Toll-free Number 1800 889 1064 or on WhatsApp Number +919310090915 or Email us at: info@theindianpharma.com along with your Identity Proof, Valid Prescription Letter, and Medical Reports. The Indian Pharma helps connect buyers with suppliers who can ship ENHERTU at the global level as per the requirement of buyers. The Indian Pharma (TIP) provides a guarantee of quality and delivery for the ENHERTU 100 mg Injections.

Is it safe to buy Enhertu online in India?

Yes, one can buy Enhertu 100 mg online at the best price from The Indian Pharma (TIP) if Enhertu is not registered or is unavailable in the country. We can help facilitate the supply of Enhertu injection through legal channels.

Related products

× How can I Help you?